teclistamab,talquetamab,daratumumab
genmab,janssen
['redirectt-1']
in 10 minutes, will present the first results of the redirectt-1 study in the session "mm clinical: new combinations and novel targets session at #eha2023. mpe interviewed her to summarise the most important results. check our comms channels after her presentation!
A network of highly efficient, effective and sustainable myeloma and AL amyloidosis patient organisations across Europe